X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STERLING BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STERLING BIOTECH SUN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 15.3 -1.8 - View Chart
P/BV x 3.6 0.1 5,200.0% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SUN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
STERLING BIOTECH
Dec-13
SUN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,20111 11,435.2%   
Low Rs7063 20,776.5%   
Sales per share (Unadj.) Rs117.526.8 438.2%  
Earnings per share (Unadj.) Rs19.6-15.0 -131.0%  
Cash flow per share (Unadj.) Rs23.8-5.5 -435.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs130.554.9 237.8%  
Shares outstanding (eoy) m2,406.60267.87 898.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.10.3 3,131.0%   
Avg P/E ratio x48.7-0.5 -10,472.2%  
P/CF ratio (eoy) x40.1-1.3 -3,148.2%  
Price / Book Value ratio x7.30.1 5,770.4%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m2,294,8131,862 123,264.6%   
No. of employees `00014.71.4 1,089.1%   
Total wages/salary Rs m47,971547 8,773.1%   
Avg. sales/employee Rs Th19,169.85,303.3 361.5%   
Avg. wages/employee Rs Th3,253.0403.8 805.5%   
Avg. net profit/employee Rs Th3,197.9-2,959.0 -108.1%   
INCOME DATA
Net Sales Rs m282,6977,181 3,936.9%  
Other income Rs m6,17043 14,482.9%   
Total revenues Rs m288,8677,223 3,999.1%   
Gross profit Rs m83,239947 8,790.7%  
Depreciation Rs m10,1352,543 398.5%   
Interest Rs m4,7694,377 109.0%   
Profit before tax Rs m74,505-5,931 -1,256.2%   
Minority Interest Rs m-11,1260-   
Prior Period Items Rs m-190-   
Extraordinary Inc (Exp) Rs m-6,8520-   
Tax Rs m9,349-1,924 -485.8%   
Profit after tax Rs m47,159-4,007 -1,177.1%  
Gross profit margin %29.413.2 223.3%  
Effective tax rate %12.532.4 38.7%   
Net profit margin %16.7-55.8 -29.9%  
BALANCE SHEET DATA
Current assets Rs m308,64614,335 2,153.1%   
Current liabilities Rs m132,47749,809 266.0%   
Net working cap to sales %62.3-494.0 -12.6%  
Current ratio x2.30.3 809.5%  
Inventory Days Days83403 20.6%  
Debtors Days Days88171 51.4%  
Net fixed assets Rs m133,60655,432 241.0%   
Share capital Rs m2,407268 898.3%   
"Free" reserves Rs m266,90913,935 1,915.4%   
Net worth Rs m314,04214,701 2,136.2%   
Long term debt Rs m31,1679,478 328.8%   
Total assets Rs m542,19673,988 732.8%  
Interest coverage x16.6-0.4 -4,683.0%   
Debt to equity ratio x0.10.6 15.4%  
Sales to assets ratio x0.50.1 537.2%   
Return on assets %9.60.5 1,912.1%  
Return on equity %15.0-27.3 -55.1%  
Return on capital %17.8-6.4 -276.2%  
Exports to sales %14.025.9 54.0%   
Imports to sales %3.10.2 1,849.3%   
Exports (fob) Rs m39,5721,860 2,127.7%   
Imports (cif) Rs m8,88212 72,804.9%   
Fx inflow Rs m42,1711,860 2,267.5%   
Fx outflow Rs m21,58325 86,711.9%   
Net fx Rs m20,5881,835 1,122.0%   
CASH FLOW
From Operations Rs m67,6941,719 3,938.7%  
From Investments Rs m-44,549-3,148 1,415.1%  
From Financial Activity Rs m-19,2431,426 -1,349.5%  
Net Cashflow Rs m3,902-3 -114,750.0%  

Share Holding

Indian Promoters % 63.7 33.9 187.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 9.9 232.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.3 39.3 21.1%  
Shareholders   133,026 21,482 619.2%  
Pledged promoter(s) holding % 0.5 55.9 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS